红日药业(300026.SZ)：产品继续纳入国家医保药品目录

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) announced that its product, Xuebijing injection, will continue to be included in the new drug catalog for the years 2026 to 2027 as part of the national medical insurance negotiations, according to the announcement made by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025 [1] Group 1 - Hongri Pharmaceutical's Xuebijing injection has been renewed under the current conditions for inclusion in the new drug catalog [1] - The new drug catalog is part of the national basic medical insurance, maternity insurance, and work-related injury insurance [1] - The negotiations for the 2026 to 2027 medical insurance renewal have been successfully concluded for the product [1]